PhaseBio Pharmaceuticals Enterprise Value

Enterprise Value of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Enterprise Value growth rates and interactive chart. Calculated as market cap + net debt. A company with a market cap of $1 billion and net cash of $500 million will have an enterprise value of $500 million. Not applicable to financial companies, due to the structure of cash on their balance sheet.


Highlights and Quick Summary

Current Enterprise Value of PhaseBio Pharmaceuticals is $84.8 Million (as of December 30, 2020)
  • Enterprise Value for the quarter ending June 29, 2021 was $125 Million (a 147.9% increase compared to previous quarter)
  • Year-over-year quarterly Enterprise Value increased by 162.55%
  • Annual Enterprise Value for 2020 was $84.8 Million (a -21.97% decrease from previous year)
  • Annual Enterprise Value for 2019 was $109 Million (a -419.29% decrease from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Enterprise Value of PhaseBio Pharmaceuticals

Most recent Enterprise Valueof PHAS including historical data for past 10 years.

Interactive Chart of Enterprise Value of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Enterprise Value for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $125.29
2020 $50.54 $84.79
2019 $108.67 $47.72 $307.06 $258.64 $108.67
2018 $-34.03 $-13.06 $-34.03

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.